Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving 2.46% from the previous trading session.
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) reached $67.74 at the closing of the latest trading day, reflecting a -6.98% change compared to its last close.
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $51.81, indicating a -3.5% shift from the previous trading day.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025
CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain unprofitable, with ex vivo therapy complexity limiting mass adoption and reinforcing the need for scalable in vivo solutions. Upcoming high-stakes clinical readouts for CTX310, CTX112, and CTX131 could significantly impact CRSP's valuation, warranting a cautious, milestone-driven approach.
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
